The Dutch biotech Synaffix, which has been active in the deal space out of the gate in 2023, is building on a deal it made with MacroGenics last year.
Synaffix announced Tuesday it has expanded an agreement with the biotech MacroGenics to license out its antibody conjugation platform, called GlycoConnect,...
